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Abstract Although Ki67 index suffers from poor repro-
ducibility, it is one of the most important prognostic
markers used by oncologists to select the treatment of
estrogen receptor (ER) positive breast cancer patients. In
this study, we aim to establish the optimal Ki67 cut-offs for
stratifying patient prognosis and to create a comprehensive
prognostic index for clinical applications. A mono-insti-
tutional cohort of 1.577 human epidermal growth factor
receptor 2 negative/ER? breast cancer patients having
complete clinical, histological, and follow-up data was
collected. The 14 and 20 % Ki67 cut-offs were correlated
to disease-free interval (DFI) and disease-specific survival
(DSS). To create a comprehensive prognostic index, we
used independent variables selected by uni/multivariate
analyses. In terms of DFI and DSS, patients bearing tumors
with Ki67\ 14 % proliferation index did not differ from
those with Ki67 values between 14 and 20 %. Patients with
tumor with Ki67[ 20 % showed the poorest prognosis.
Moreover, to tumor size, the number of metastatic lymph
nodes and Ki67[ 20 % was given a score value, varying
depending on definite cut-offs and used to create a prog-
nostic index, which was applied to the population. Patients
with a prognostic index C3 were characterized by signifi-
cant risk of relapse [DFI: Hazard Ratio (HR) = 4.74,
p\ 0.001] and death (DSS: HR = 5.03, p\ 0.001). We
confirm that the 20 % Ki67 cut-off is the best to stratify
high-risk patients in luminal breast cancers, and we suggest
to integrate it with other prognostic factors, to better
stratify patients at risk of adverse outcome.
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Abbreviations
ER Estrogen receptor
HER2 Human epidermal growth factor receptor 2
DFI Disease-free interval
DSS Disease-specific survival
PR Progesterone receptor
AIC Akaike information criterion
NCCN National comprehensive cancer network
Introduction
The immunohistochemical surrogate of molecular sub-
classes of breast cancers proposed by the Saint Gallen
Consensus Meetings [1–3] is largely used to classify
patients in different risk categories. However, the main
drawback of this classification is the low consistency in
classifying Luminal A and Luminal B/HER2-negative
(HER2-) carcinomas. Actually, both of them are estrogen
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receptor positive (ER?) and HER2-, but Luminal B cat-
egory should identify patients with worse prognosis,
endorsed for chemotherapy in addition to hormone block-
age. Therefore, to differentiate Luminal A from Luminal
B/HER2- breast cancers carries important therapeutic
implications. For this aim, the Saint Gallen Guidelines [1]
recommend to assess the proliferation index by Ki67, a
nuclear marker of cell proliferation that is expressed in all
cell cycle phases, except G0 [4]. A Luminal B breast
cancer should show a higher proliferation index than
Luminal A; however, the Ki67 cut-off for differentiating
these two categories changed over time. The 2011 Saint
Gallen Consensus Meeting defined as ‘‘low proliferation’’
tumors with a Ki67 index\14 % [3], a cut-off established
by comparison with PAM50 intrinsic multigene molecular
test classification of Luminal cancers [5]. Otherwise, dur-
ing the 2013 Saint Gallen Conference, the majority of
panelists voted that a threshold of C20 % was indicative of
‘‘high’’ Ki67 status. At the same time, several works
reported low reproducibility of Ki67 results, mainly in the
subset of cancers with intermediate proliferation activity
(between 15 and 30 %) [6–10]. Thus, in March 2015,
during the last Saint Gallen Conference [1], the use of the
median Ki67 value of local laboratory was proposed as the
cut-off, and accepted by the panel of experts.
In our Institution, the median Ki67 value (tested on 547
consecutive luminal invasive breast cancers, operated
between January and December 2014) is 14 %. Thus, we
analyzed a large retrospective cohort of Luminal ER?/
HER2- breast cancers, with long follow-up, with the fol-
lowing aims: (1) to establish which is the optimal Ki67 cut-
off (14 vs 20 %) to stratify cases according to disease-free
interval (DFI) and disease-specific survival (DSS) at 5 and
10 years, and (2) to assess the prognostic significance of
intermediate Ki67 values. In addition, considering that
patient prognosis depends on tumor and patient character-
istics, we investigated the role of proliferation activity
within a comprehensive prognostic index, which uses
independent variables to stratify patients having ‘‘good’’ or
‘‘poor’’ prognosis.
Patients and methods
Study design and population
We investigated 1688 female patients with ER?/HER2-
primary breast cancers who underwent surgery from June
1994 to December 2012 at the Breast Unit of the Citta` della
Salute e della Scienza of Torino, University Hospital of
Torino, Italy. Ethical approval for this study was obtained
from the Ethical Committee of our Institution.
The following clinico-pathological data were obtained
from clinical charts: age at diagnosis, type of surgery
(conservative surgery vs radical mastectomy), therapy,
type, and site of recurrence. In addition, data regarding size
(\15 vs C15 mm), histological type and grade of tumor,
nodal involvement, vascular invasion, Progesterone
Receptor (PR), ER, HER2, and Ki-67 was obtained from
pathological reports. In particular, for what concerns Ki67,
we set cut-points at 14 % (low) and 20 % (high), and of PR
at 20 % as recommended by St. Gallen experts [2, 3].
Complete clinical and histopathological data were avail-
able for 1577 out 688 patients.
Statistical analyses
Pearson’s Chi-square test and Student’s t test were pre-
liminary performed to compare categorical and continuous
variables, respectively, and to evaluate potential differ-
ences in the variable distribution among groups. The dis-
ease-free interval (DFI) was calculated from the date of
surgical excision of the primary tumor to the date of the
first relapse or last check-up. Disease-specific survival
(DSS) was calculated from the surgical excision date of the
primary tumor to the date of breast cancer death or last
check-up. Survival distribution curves were plotted using
the Kaplan–Meyer method, and the statistical comparisons
were performed using the log-rank test. Cox regression
analyses were carried out on DFI and DSS to calculate
crude and adjusted HRs and 95 % CIs for the different
study group. Cases lost to follow-up and cases with a non-
breast cancer related deaths were censored at the last fol-
low-up control. A model was created for evaluating the
prognostic role of different variables. The proportional
hazard assumption was assessed with the Schoenfeld
residuals. This did not give reasons to suspect violation of
this assumption. The nature of variables (continue/cate-
gorical) included in the model was evaluated considering
literature reports and the results of the log-likelihood ratio
test. Akaike information criterion (AIC) was used for
model selection. All statistical tests were two sided. p val-
ues\0.05 were considered significant. Statistical analyses
were performed using Stata/SE12.0 Statistical Software
(STATA, College Station, TX).
Results
The characteristics of the 1688 patients with ER?/HER2-
breast cancer stratified according to Ki67 cut-offs are
reported in Tables 1 and 2. DFI and DSS were evaluated in
patients with low (\14 %), intermediate (14–19 %) and
high (C20 %) Ki67 levels. Patients affected by cancers
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with low and intermediate Ki67 values had similar DFI and
DSS, whereas patients with high Ki67 proliferation index
had lower DFI and DSS than patients in the two former
groups (Log-rank test DFI p\ 0.001; DSS p\ 0.001),
Fig. 1.
Univariate Cox analyses estimates reported in Table 2
showed that tumor size C15 mm, nodal involvement, high
grade, and vascular invasion negatively impact on DFI and
DSS, together with a high-Ki67 index. As expected, can-
cers having such features were treated with more aggres-
sive surgery and radiotherapy (Table 1). PR[20 % failed
to play a favorable prognostic role on DSS (Table 3).
Multivariable analyses (Table 4) were performed on
1577 patients with complete clinical and histopathological
data. The proportionality assumption was satisfied both on
DFI (p = 0.6469) and DSS (p = 0.8008). Tumor size
C15 mm, nodal involvement, 20 % Ki67 cut-point main-
tained an unfavorable role on DFI and DSS.
To create a comprehensive index associated to ‘‘good’’
and ‘‘poor’’ prognosis and based on multivariate analysis, a
score was attributed to each significant variable according to
its HR. Thus, a score value of 1was given to tumors[15 mm
and tumors with Ki67 C 20 %, whereas a score 0 was given
to tumorsB15 mmand tumorswithKi67\20 %. Four score
Table 1 The characteristics of the 1688 patients with ER?/HER2- breast cancer stratified according to Ki67 cut-offs
Total Ki67\14 % Ki67 C14 % p Ki67\20 % Ki67 C20 % p
Age at diagnosis
Median, interval 62 (23–92) 62 (34–87) 62 (23–92) 0.674 62 (23–92) 61 (27–88) 0.141
LN metastatic (n) (missing 5)
0 1133 596 537 \0.001 834 299 \0.001
1–3 405 177 228 249 156
4–9 96 34 62 48 48
[9 49 14 35 18 31
Tumor size (mm) (missing 58)
\15 912 527 385 \0.001 717 195 \0.001
C15 718 277 441 409 309
Tumor grade (missing 1)
1 634 462 172 \0.001 564 70 \0.001
2 806 333 473 534 272
3 247 27 220 53 194
Vascular invasion (missing 13)
No 1104 637 467 \0.001 858 246 \0.001
Si 571 178 393 283 288
PgR% (missing 111)
\20% 337 151 186 0.023 212 125 \0.001
C20% 1,240 642 598 891 349
Histotype (missing 138)
DC 961 420 541 \0.001 608 353 \0.001
ILC 198 134 332 253 79
IDC ? ILC 157 63 94 94 63
other 234 139 95 194 40
Surgery (missing 5)
Conservative 1180 608 572 \0.001 655 447 \0.001
Mastectomy 503 213 290 234 236
Radiotherapy (missing 1)
No 462 196 266 \0.001 282 180 \0.001
Yes 1215 624 591 862 353
Site of progression
Contralateral 16 7 9 0.329 8 8 0.483
Regional 51 13 38 17 34
Distant 94 25 69 36 58
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values were used for lymph nodes (0: lymph nodes free of
metastases; 1: from 1 to 3 metastatic lymph nodes, 2: from 4
to 9metastatic lymph nodes; 3:more than 9metastatic lymph
nodes). The comprehensive prognostic index was created
using the following formula: (tumor size score
value) ? (number of metastatic lymph nodes score
value) ? (Ki67 score value), determining a range of 0–5.
Kaplan Maier analysis was then carried out for each value.
We found that 575 had a final index of 0; 481 of 1; 303 of 2,
147 of 3, 40 of 4, and 21 of 5. Following the performance
curves, we set the index cut-off at 3, indicating\3 a good
prognosis and C3 a poor prognosis. Patients with an index
C3 had a significant increased risk of relapse (DFI:
HR = 4.74, CI 3.46–6.51, p\ 0.001) and of death (DSS:
HR = 5.03, CI 3.19–7.94, p\ 0.001) Fig. 2.
We then analyzed the outcome of patients according to
treatment (1040 hormonal therapy alone; 451 chemother-
apy followed by hormone therapy). Eighty-six patients
were not treated (comorbidities, older age, therapy refused)
and were thus excluded from further analyses. Treatment
type did not change DFI and DSS of patients with a score
\3 (good prognosis) Fig. 3. On the contrary, patients with
poor prognosis (score C 3) treated with hormonal therapy
alone had a DSS disadvantage, compared to patients treated
with adjuvant chemotherapy before hormonal treatment
Fig. 4.
Discussion
The first result of our study is that Luminal breast cancer
patients with low (\14 %) and intermediate (14–19 %)
Ki67 have the same DFI and DSS and a better prognosis
Fig. 1 DFI and DSS in low, intermediate, and high Ki67 patients
Table 2 Classification on the basis of Ki67 and PgR values
ER? Luminal A
(Ki67 low,
PgR high)
Luminal B
(Ki67 high or PgR
negative/low)
Ki67
\14 % 642 151
C14 % – 784
Ki67
\20 % 891 212
C20 % – 474
Ki67 C 20 % Luminal A Luminal B
Ki67 (%)
\14 642 151
14–19 249 61
C20 – 474
Ki67 (%) PgR%\20 % PgR% C20 %
Luminal A Luminal B Luminal A Luminal B
\14 – 151 642 –
14–19 – 61 249 –
C20 – 125 0 349
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Table 3 Univariate analyses on
DFI and DSS
Variable DFI DSS
HR CI p HR CI p
Ki67 C 14 % 2.33 1.65–3.29 \0.001 2.53 1.50–4.26 \0.001
Ki67 C 20 % 3.24 2.35–4.45 \0.001 3.77 2.32–6.13 \0.001
Ki67 %
\14 % 1 1
14–20 % 0.90 0.51–1.59 0.710 0.68 0.26–1.83 0.454
C20 % 3.14 2.21–4.47 \0.001 3.44 2.03–5.84 \0.001
PgR C 20% 0.67 0.47–0.95 0.026 0.65 0.39–1.10 0.107
Mastectomy versus conservative surgery 3.70 2.71–5.07 \0.001 3.87 2.44–6.15 \0.001
LN metastatic
N0 1
N1 1.88 1.30–2.74 0.001 1.36 0.76–2.45 0.303
N2 4.78 3.03–7.56 \0.001 4.91 2.63–9.20 \0.001
N3 7.34 4.41–12.2 \0.001 6.75 3.32–13.7 \0.001
Tumor size C15 3.62 2.52–5.21 \0.001 4.24 2.45–7.35 \0.001
Tumor grade
1 1 1
2 1.94 1.28–2.95 0.002 1.92 1.00–3.67 0.048
3 3.95 2.53–6.16 \0.001 5.00 2.61–9.57 \0.001
Vascular invasion 2.71 1.98–3.71 \0.001 3.00 1.87–4.82 \0.001
Histotype
IDC 1 1
ILC 1.02 0.69–1.51 0.906 1.17 0.68–2.01 0.577
IDC ? ILC 0.79 0.47–1.36 0.413 0.657 0.29–1.47 0.302
Other 0.72 0.43–1.19 0.197 0.707 0.33–1.49 0.358
Radiotherapy 0.36 0.28–0.49 \0.001 0.44 0.28–0.71 0.001
Table 4 Multivariate analyses
on DFI and DSS
Variable DFI DSS
HR CI p HR CI p
Age at diagnosis 0.99 0.97–1.00 0.355 1.00 0.98–1.03 0.549
Tumor size C 15 2.06 1.35–3.14 0.001 2.78 1.42–5.41 0.003
Vascular Invasion 1.14 0.76–1.73 0.522 1.62 0.86–3.05 0.138
PgR C 20 % 0.70 0.47–1.02 0.066 0.66 0.38–1.16 0.153
Metastatic LN
N0 1 1
N1 1.53 0.98–2.40 0.061 1.13 0.57–2.26 0.724
N2 3.03 1.69–5.44 0.000 2.89 1.29–6.47 0.010
N3 4.11 2.19–7.67 0.000 3.41 1.43–8.12 0.006
Tumor grade
1 1 1
2 1.15 0.71–1.88 0.569 1.10 0.51–2.36 0.806
3 1.06 0.59–1.89 0.851 1.09 0.46–2.58 0.836
Ki67 C 20 % 2.35 1.56–3.55 0.000 2.37 1.26–4.47 0.008
Global test DFI p = 0.6429; DSS p = 0.8008
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than patients with high (C20 %) Ki67. This result confirms
that, within ER?/HER2- breast cancers, the 20 % Ki67
cut-off can reliably (1) discriminate patients at low or high
risk of recurrence and death, and (2) stratify patients at
higher risk, eligible to adjuvant chemotherapy before hor-
mone therapy.
The usefulness of Ki67 for decision on breast cancer
management is a matter of discussion. A number of
oncologists advise not to rely on Ki67 in the clinical
practice, because of its low reproducibility [2–11]. Addi-
tionally, the American National Comprehensive Cancer
Network (NCCN) guidelines do not provide any
Fig. 2 DFI and DSS in patients stratified on the basis of good (\3) or poor (C3) score
Fig. 3 DFI and DSS in patients with good score (\3) stratified on the basis of therapy
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information regarding Ki67 immunohistochemical assess-
ment and its role in breast cancer prognosis [12].
However, in Europe, the Saint Gallen Consensus
Meeting had suggested to use Ki67 for classifying Luminal
cancers since 2009. Still, uncertainty regarding the defini-
tion of highly proliferating tumors remains. In 2011, a cut-
off of 14 % [3] was proposed, on the basis of the study by
Cheang et al. [5], but 2 years later, it was upgraded to 20 %
[2]. In the same year, Denkert et al. [13] proposed to
considered Ki67 a continuum variable and suggested that
the cut-points are context dependent and may change
according to the prognostic or predictive role given to Ki67
itself. Thus, they suggested that the scientific community
could define Ki67 cut-points depending on the study pur-
pose [14]. To solve the literature ambiguities, we evaluated
Ki67 in a subset of patients with ER? (Luminal) breast
cancer, with the aim to verify its impact on prognosis. First
of all, we calculated the median value of Ki67 in our case
series, as suggested by the last Saint Gallen Consensus
Meeting [1] and showed that it corresponded to the value of
14 % identified by Cheang [5] as able to discriminate
Luminal A from Luminal B molecular subtypes. Patients
with a low (\14 %) and intermediate (14–19 %) Ki67
value showed a better DFI and DSS than those with higher
Ki67 (C20 %). As a consequence, when the purpose is to
recognize high-risk patients, the 20 % cut-off is more
reliable and reproducible than the 14 % cut-off. Moreover,
Cserni et al. [15] showed that, in the routine practice, the
proportion of Ki67 positive cells ‘‘tends to cluster around
values ending with 5 or 0,’’ and accordingly, they proposed
to select cut-off values ending with one of these two
numbers.
Although we confirm that Ki67 is a reliable marker for
identifying patients at low and high risk of recurrences/
death, we firmly believe that Ki67 percentage has to be
assessed following International Guidelines [16] and that
the laboratory should be strictly subjected to local and
external quality control assurance [17].
Moreover, in line with several studies suggesting that
one marker is not sufficient to stratify prognosis of breast
cancer patients, we designed a comprehensive prognostic
index combining Ki67 with tumor size and number of
metastatic lymph nodes. This index was highly predictive
of DSS and DFI, at both uni- and multivariate analyses,
confirming that tumor burden and proliferative index
remain the most important parameters in ER? breast
cancer prognosis, as suggested by several other studies
[18–22]. Actually, both tumor size and the number of
positive axillary lymph nodes are traditionally accepted as
important prognostic factors in breast cancer patients [23,
24], and molecular tools such as Endopredict and
PAM50 include these parameters, in association with
specific gene expression, to create a recurrence score called
EPclin and Prosigna ROR score, respectively. Since a
number of genes in these assays are related to proliferative
index and to ER pathway, we can reasonably suggest that
the use of our prognostic index in Luminal cancer could
‘‘surrogate’’ the multigene prognostic test results.
Fig. 4 DFI and DSS in patients with poor score (C3) stratified on the basis of therapy
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In addition, we found that, within the subset of patients
with a poor prognostic index (C3), those treated with
hormonal therapy alone showed a poorer DSS than those
receiving also adjuvant chemotherapy. This result suggests
that our prognostic index may be useful to identify patients
that need a more aggressive treatment.
Although our study is based on a retrospective and a
monocentric dataset of patients, which could represent pos-
sible biases, in our Institute, two different pathologists,
skilled in breast pathology, assess Ki67 expression, and
treatment is decided during multidisciplinary meetings,
allowing for discussion among different clinicians.
In conclusion, we confirm the reliability of Ki67 as a
prognostic marker in Luminal breast cancers, using a cut-
off value of 20 %, and we stress the important role of Ki67
in the clinical management of patients. In addition, waiting
for molecular test accessibility through the healthcare
system, Ki67 together with tumor size and lymph nodal
status may be useful to identify ER? breast cancer patients
with adverse prognostic outcome that need combined
chemotherapy and hormonal therapy.
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